drugset / Trial / NCT00246519

Pharmacogenomic Evaluation of Antihypertensive Responses

NCT00246519

Phase 4 Completed 1701 enrolled University of Florida
RandomizedCrossoverOpen-labelTreatment

Summary

There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging. In fact, it is estimated that only 34% of people with hypertension have their blood pressure under control. The hypothesis is that genetic differences between individuals influence their response to antihypertensive medications. This study is aimed at determining the genetic factors that may influence a person's response to either a beta-blocker or a thiazide diuretic. The hope is that through this research, we may someday be able to use an individual's genetic information to guide the selection of their blood pressure medicine, leading to better control of blood pressure, and less need for the current trial and error process.

Timeline

Start
2005-10
Primary completion
2010-12
Completion
2010-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Atenolol Other / unclassified 50 mg
Subject Atenolol Other / unclassified 100 mg
Subject Hydrochlorothiazide Unknown 12.5 mg Oral
Subject Hydrochlorothiazide Unknown 25 mg Oral

Indications